Literature DB >> 34890525

Randomized two-stage optimal design for interval-censored data.

Guogen Shan1.   

Abstract

Interval-censored data occur in a study where the exact event time of each participant is not observed but it is known to be within a certain time interval. Multiple tests were proposed for such data, including the logrank test by Sun, the proportional hazard test by Finkelstein, and the Wilcoxon-type test by Peto and Peto. We propose sample size calculations based on these tests for a parallel one-stage or two-stage design. When the proportional hazard assumption is met, the proportional hazard test and the logrank test need smaller sample sizes than the Wilcoxon-type test, and the sample size savings are substantial. But this trend is reversed when the proportional hazard assumption does not hold, and the sample size savings using the Wilcoxon-type test are sizable. An example from a lung cancer clinical trial is used to illustrate the application of the proposed sample size calculations.

Entities:  

Keywords:  Interval-censored data; repeated measures; sample size; survival data; two-stage designs

Mesh:

Year:  2021        PMID: 34890525      PMCID: PMC9133004          DOI: 10.1080/10543406.2021.2009499

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.503


  24 in total

Review 1.  Integrating ADNI results into Alzheimer's disease drug development programs.

Authors:  Jeffrey L Cummings
Journal:  Neurobiol Aging       Date:  2010-05-05       Impact factor: 4.673

2.  Randomized two-stage Phase II clinical trial designs based on Barnard's exact test.

Authors:  Guogen Shan; Changxing Ma; Alan D Hutson; Gregory E Wilding
Journal:  J Biopharm Stat       Date:  2013       Impact factor: 1.051

3.  Accurate confidence intervals for proportion in studies with clustered binary outcome.

Authors:  Guogen Shan
Journal:  Stat Methods Med Res       Date:  2020-04-03       Impact factor: 3.021

4.  Exact Unconditional Tests for Dichotomous Data When Comparing Multiple Treatments With a Single Control.

Authors:  Guogen Shan; Carolee Dodge-Francis; Gregory E Wilding
Journal:  Ther Innov Regul Sci       Date:  2020-01-06       Impact factor: 1.778

5.  Optimal adaptive two-stage designs for early phase II clinical trials.

Authors:  Guogen Shan; Gregory E Wilding; Alan D Hutson; Shawn Gerstenberger
Journal:  Stat Med       Date:  2015-11-03       Impact factor: 2.373

6.  Exact inference for the random-effect model for meta-analyses with rare events.

Authors:  Jessica Gronsbell; Chuan Hong; Lei Nie; Ying Lu; Lu Tian
Journal:  Stat Med       Date:  2019-12-09       Impact factor: 2.373

7.  Exact confidence limits for the response rate in two-stage designs with over- or under-enrollment in the second stage.

Authors:  Guogen Shan
Journal:  Stat Methods Med Res       Date:  2016-07-07       Impact factor: 3.021

8.  Statistical advances in clinical trials and clinical research.

Authors:  Guogen Shan; Sarah Banks; Justin B Miller; Aaron Ritter; Charles Bernick; Joseph Lombardo; Jeffrey L Cummings
Journal:  Alzheimers Dement (N Y)       Date:  2018-06-14

9.  Machine learning methods to predict amyloid positivity using domain scores from cognitive tests.

Authors:  Guogen Shan; Charles Bernick; Jessica Z K Caldwell; Aaron Ritter
Journal:  Sci Rep       Date:  2021-03-01       Impact factor: 4.379

10.  Comparing survival functions with interval-censored data in the presence of an intermediate clinical event.

Authors:  Sohee Kim; Jinheum Kim; Chung Mo Nam
Journal:  BMC Med Res Methodol       Date:  2018-10-01       Impact factor: 4.615

View more
  1 in total

1.  Monte Carlo cross-validation for a study with binary outcome and limited sample size.

Authors:  Guogen Shan
Journal:  BMC Med Inform Decis Mak       Date:  2022-10-17       Impact factor: 3.298

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.